{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:47:55Z","timestamp":1768531675124,"version":"3.49.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T00:00:00Z","timestamp":1519948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T00:00:00Z","timestamp":1519948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic myelogenous leukemia (CML) caused by hematopoietic stem cells expressing the <jats:italic>Bcr-Abl<\/jats:italic> fusion gene may be controlled by Bcr-Abl tyrosine kinase inhibitors (TKIs). However, CML-initiating cells are resistant to TKIs and may persist as minimal residual disease. We demonstrate that mice deficient in <jats:italic>Sipa1<\/jats:italic>, which encodes Rap1 GTPase-activating protein, rarely develop CML upon transfer of primary hematopoietic progenitor cells (HPCs) expressing <jats:italic>Bcr-Abl<\/jats:italic>, which cause lethal CML disease in wild-type mice. Resistance requires both T cells and nonhematopoietic cells. <jats:italic>Sipa1<\/jats:italic><jats:sup>\u2212\/\u2212<\/jats:sup> mesenchymal stroma cells (MSCs) show enhanced activation and directed migration to <jats:italic>Bcr-Abl<\/jats:italic><jats:sup>+<\/jats:sup> cells in tumor tissue and preferentially produce Cxcl9, which in turn recruits <jats:italic>Sipa1<\/jats:italic><jats:sup>\u2212\/\u2212<\/jats:sup> memory T cells that have markedly augmented chemotactic activity. Thus, <jats:italic>Sipa1<\/jats:italic> deficiency uncovers a host immune mechanism potentially capable of eradicating <jats:italic>Bcr-Abl<\/jats:italic><jats:sup>+<\/jats:sup> HPCs via coordinated interplay between MSCs and immune T cells, which may provide a clue for radical control of human CML.<\/jats:p>","DOI":"10.1038\/s41467-018-03307-8","type":"journal-article","created":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T15:42:43Z","timestamp":1519659763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Sipa1 deficiency unleashes a host-immune mechanism eradicating chronic myelogenous leukemia-initiating cells"],"prefix":"10.1038","volume":"9","author":[{"given":"Yan","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Sumida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusuke","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagahiro","family":"Minato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,2]]},"reference":[{"key":"3307_CR1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/35077241","volume":"411","author":"LA Liotta","year":"2001","unstructured":"Liotta, L. A. & Kohn, E. C. The microenvironment of the tumour-host interface. Nature 411, 375\u2013379 (2001).","journal-title":"Nature"},{"key":"3307_CR2","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev-immunol-020711-075008","volume":"30","author":"G Trinchieri","year":"2012","unstructured":"Trinchieri, G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu. Rev. Immunol. 30, 677\u2013706 (2012).","journal-title":"Annu. Rev. Immunol."},{"key":"3307_CR3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrc1877","volume":"6","author":"R Kalluri","year":"2006","unstructured":"Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer 6, 392\u2013401 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"3307_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","volume":"29","author":"MD Vesely","year":"2011","unstructured":"Vesely, M. D., Kershaw, M. H., Schreiber, R. D. & Smyth, M. J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235\u2013271 (2011).","journal-title":"Annu. Rev. Immunol."},{"key":"3307_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.immuni.2013.07.008","volume":"39","author":"J Galon","year":"2013","unstructured":"Galon, J., Angell, H. K., Bedognetti, D. & Marincola, F. M. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39, 11\u201326 (2013).","journal-title":"Immunity"},{"key":"3307_CR6","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science 331, 1565\u20131570 (2011).","journal-title":"Science"},{"key":"3307_CR7","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99, 12293\u201312297 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3307_CR8","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455\u20132465 (2012).","journal-title":"N. Engl. J. Med."},{"key":"3307_CR9","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"3307_CR10","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor, F. et al. Dynamics of chronic myeloid leukaemia. Nature 435, 1267\u20131270 (2005).","journal-title":"Nature"},{"key":"3307_CR11","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","volume":"21","author":"B Zhang","year":"2012","unstructured":"Zhang, B. et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell 21, 577\u2013592 (2012).","journal-title":"Cancer Cell"},{"key":"3307_CR12","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","volume":"20","author":"D Reynaud","year":"2011","unstructured":"Reynaud, D. et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 20, 661\u2013673 (2011).","journal-title":"Cancer Cell"},{"key":"3307_CR13","doi-asserted-by":"publisher","first-page":"e0134026","DOI":"10.1371\/journal.pone.0134026","volume":"10","author":"E Supper","year":"2015","unstructured":"Supper, E., Tahir, S., Imai, T., Inoue, J. & Minato, N. Modification of gene expression, proliferation, and function of OP9 stroma cells by Bcr-Abl-expressing leukemia cells. PLoS ONE 10, e0134026 (2015).","journal-title":"PLoS ONE"},{"key":"3307_CR14","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton, A. et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119, 1501\u20131510 (2012).","journal-title":"Blood"},{"key":"3307_CR15","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin, A. S. et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396\u2013409 (2011).","journal-title":"J. Clin. Invest."},{"key":"3307_CR16","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1056\/NEJMp038130","volume":"349","author":"B Lowenberg","year":"2003","unstructured":"Lowenberg, B. Minimal residual disease in chronic myeloid leukemia. N. Engl. J. Med. 349, 1399\u20131401 (2003).","journal-title":"N. Engl. J. Med."},{"key":"3307_CR17","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"TL Holyoake","year":"2017","unstructured":"Holyoake, T. L. & Vetrie, D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood 129, 1595\u20131606 (2017).","journal-title":"Blood"},{"key":"3307_CR18","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s00262-009-0703-x","volume":"58","author":"S Rusakiewicz","year":"2009","unstructured":"Rusakiewicz, S., Madrigal, A., Travers, P. & Dodi, A. I. BCR\/ABL-specific CD8+T cells can be detected from CML patients, but are only expanded from healthy donors. Cancer Immunol. Immunother. 58, 1449\u20131457 (2009).","journal-title":"Cancer Immunol. Immunother."},{"key":"3307_CR19","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/79526","volume":"6","author":"JJ Molldrem","year":"2000","unstructured":"Molldrem, J. J. et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6, 1018\u20131023 (2000).","journal-title":"Nat. Med."},{"key":"3307_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11899-013-0190-1","volume":"9","author":"M Ilander","year":"2014","unstructured":"Ilander, M., Hekim, C. & Mustjoki, S. Immunology and immunotherapy of chronic myeloid leukemia. Curr. Hematol. Malig. Rep. 9, 17\u201323 (2014).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"3307_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/cdd.2014.89","volume":"22","author":"C Riether","year":"2015","unstructured":"Riether, C., Schurch, C. M. & Ochsenbein, A. F. Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ. 22, 187\u2013198 (2015).","journal-title":"Cell Death Differ."},{"key":"3307_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/jb\/mvg180","volume":"134","author":"M Hattori","year":"2003","unstructured":"Hattori, M. & Minato, N. Rap1 GTPase: functions, regulation, and malignancy. J. Biochem. 134, 479\u2013484 (2003).","journal-title":"J. Biochem."},{"key":"3307_CR23","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1128\/MCB.20.6.1956-1969.2000","volume":"20","author":"K Katagiri","year":"2000","unstructured":"Katagiri, K. et al. Rap1 is a potent activation signal for leukocyte function-associated antigen 1 distinct from protein kinase C and phosphatidylinositol-3-OH kinase. Mol. Cell. Biol. 20, 1956\u20131969 (2000).","journal-title":"Mol. Cell. Biol."},{"key":"3307_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.tcb.2011.07.001","volume":"21","author":"M Gloerich","year":"2011","unstructured":"Gloerich, M. & Bos, J. L. Regulating Rap small G-proteins in time and space. Trends Cell Biol. 21, 615\u2013623 (2011).","journal-title":"Trends Cell Biol."},{"key":"3307_CR25","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.cell.2007.05.018","volume":"129","author":"JL Bos","year":"2007","unstructured":"Bos, J. L., Rehmann, H. & Wittinghofer, A. GEFs and GAPs: critical elements in the control of small G proteins. Cell 129, 865\u2013877 (2007).","journal-title":"Cell"},{"key":"3307_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1535-6108(03)00163-6","volume":"4","author":"D Ishida","year":"2003","unstructured":"Ishida, D. et al. Myeloproliferative stem cell disorders by deregulated Rap1 activation in SPA-1-deficient mice. Cancer Cell 4, 55\u201365 (2003).","journal-title":"Cancer Cell"},{"key":"3307_CR27","doi-asserted-by":"publisher","first-page":"10919","DOI":"10.1073\/pnas.1834525100","volume":"100","author":"D Ishida","year":"2003","unstructured":"Ishida, D. et al. Antigen-driven T cell anergy and defective memory T cell response via deregulated Rap1 activation in SPA-1-deficient mice. Proc. Natl Acad. Sci. USA 100, 10919\u201310924 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3307_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.immuni.2006.02.007","volume":"24","author":"D Ishida","year":"2006","unstructured":"Ishida, D. et al. Rap1 signal controls B cell receptor repertoire and generation of self-reactive B1a cells. Immunity 24, 417\u2013427 (2006).","journal-title":"Immunity"},{"key":"3307_CR29","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1016\/j.yexcr.2013.04.009","volume":"319","author":"N Minato","year":"2013","unstructured":"Minato, N. Rap G protein signal in normal and disordered lymphohematopoiesis. Exp. Cell Res. 319, 2323\u20132328 (2013).","journal-title":"Exp. Cell Res."},{"key":"3307_CR30","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/ng1635","volume":"37","author":"YG Park","year":"2005","unstructured":"Park, Y. G. et al. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat. Genet. 37, 1055\u20131062 (2005).","journal-title":"Nat. Genet."},{"key":"3307_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1349-7006.2008.01011.x","volume":"100","author":"N Minato","year":"2009","unstructured":"Minato, N. & Hattori, M. Spa-1 (Sipa1) and Rap signaling in leukemia and cancer metastasis. Cancer Sci. 100, 17\u201323 (2009).","journal-title":"Cancer Sci."},{"key":"3307_CR32","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/j.1349-7006.2011.01876.x","volume":"102","author":"Y Shimizu","year":"2011","unstructured":"Shimizu, Y. et al. SPA-1 controls the invasion and metastasis of human prostate cancer. Cancer Sci. 102, 828\u2013836 (2011).","journal-title":"Cancer Sci."},{"key":"3307_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.yexcr.2017.02.026","volume":"352","author":"T Takahara","year":"2017","unstructured":"Takahara, T. et al. SIPA1 promotes invasion and migration in human oral squamous cell carcinoma by ITGB1 and MMP7. Exp. Cell Res. 352, 357\u2013363 (2017).","journal-title":"Exp. Cell Res."},{"key":"3307_CR34","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1073\/pnas.90.8.3755","volume":"90","author":"ML Gishizky","year":"1993","unstructured":"Gishizky, M. L., Johnson-White, J. & Witte, O. N. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc. Natl Acad. Sci. USA 90, 3755\u20133759 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3307_CR35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ceb.2014.06.005","volume":"30","author":"JE Bear","year":"2014","unstructured":"Bear, J. E. & Haugh, J. M. Directed migration of mesenchymal cells: where signaling and the cytoskeleton meet. Curr. Opin. Cell Biol. 30, 74\u201382 (2014).","journal-title":"Curr. Opin. Cell Biol."},{"key":"3307_CR36","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren, R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 5, 172\u2013183 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"3307_CR37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ccr.2004.10.015","volume":"6","author":"BJ Huntly","year":"2004","unstructured":"Huntly, B. J. et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6, 587\u2013596 (2004).","journal-title":"Cancer Cell"},{"key":"3307_CR38","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","volume":"118","author":"JC Chomel","year":"2011","unstructured":"Chomel, J. C. et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 118, 3657\u20133660 (2011).","journal-title":"Blood"},{"key":"3307_CR39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah, N. P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117\u2013125 (2002).","journal-title":"Cancer Cell"},{"key":"3307_CR40","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nm.4336","volume":"23","author":"A Giustacchini","year":"2017","unstructured":"Giustacchini, A. et al. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat. Med. 23, 692\u2013702 (2017).","journal-title":"Nat. Med."},{"key":"3307_CR41","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1182\/blood.V88.9.3522.bloodjournal8893522","volume":"88","author":"GJ Bosch","year":"1996","unstructured":"Bosch, G. J., Joosten, A. M., Kessler, J. H., Melief, C. J. & Leeksma, O. C. Recognition of BCR-ABL positive leukemic blasts by human CD4+T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 88, 3522\u20133527 (1996).","journal-title":"Blood"},{"key":"3307_CR42","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1172\/JCI488","volume":"101","author":"P Yotnda","year":"1998","unstructured":"Yotnda, P. et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J. Clin. Invest. 101, 2290\u20132296 (1998).","journal-title":"J. Clin. Invest."},{"key":"3307_CR43","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/ncb3570","volume":"19","author":"BO Zhou","year":"2017","unstructured":"Zhou, B. O. et al. Bone marrow adipocytes promote the regeneration of stem cells and haematopoiesis by secreting SCF. Nat. Cell Biol. 19, 891\u2013903 (2017).","journal-title":"Nat. Cell Biol."},{"key":"3307_CR44","doi-asserted-by":"publisher","first-page":"9059","DOI":"10.1128\/MCB.24.20.9059-9069.2004","volume":"24","author":"A Farina","year":"2004","unstructured":"Farina, A. et al. Bromodomain protein Brd4 binds to GTPase-activating SPA-1, modulating its activity and subcellular localization. Mol. Cell. Biol. 24, 9059\u20139069 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"3307_CR45","doi-asserted-by":"publisher","first-page":"6380","DOI":"10.1073\/pnas.0710331105","volume":"105","author":"NP Crawford","year":"2008","unstructured":"Crawford, N. P. et al. Bromodomain 4 activation predicts breast cancer survival. Proc. Natl Acad. Sci. USA 105, 6380\u20136385 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3307_CR46","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1152\/physrev.1999.79.4.1283","volume":"79","author":"CH Heldin","year":"1999","unstructured":"Heldin, C. H. & Westermark, B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79, 1283\u20131316 (1999).","journal-title":"Physiol. Rev."},{"key":"3307_CR47","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1152\/physrev.1996.76.1.69","volume":"76","author":"L Ronnov-Jessen","year":"1996","unstructured":"Ronnov-Jessen, L., Petersen, O. W. & Bissell, M. J. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol. Rev. 76, 69\u2013125 (1996).","journal-title":"Physiol. Rev."},{"key":"3307_CR48","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1172\/JCI0215970","volume":"109","author":"RJ Akhurst","year":"2002","unstructured":"Akhurst, R. J. TGF-beta antagonists: why suppress a tumor suppressor? J. Clin. Invest. 109, 1533\u20131536 (2002).","journal-title":"J. Clin. Invest."},{"key":"3307_CR49","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1002\/jcp.24347","volume":"228","author":"UM Polanska","year":"2013","unstructured":"Polanska, U. M. & Orimo, A. Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J. Cell. Physiol. 228, 1651\u20131657 (2013).","journal-title":"J. Cell. Physiol."},{"key":"3307_CR50","doi-asserted-by":"publisher","first-page":"4966","DOI":"10.1073\/pnas.0401064101","volume":"101","author":"C Kuperwasser","year":"2004","unstructured":"Kuperwasser, C. et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl Acad. Sci. USA 101, 4966\u20134971 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3307_CR51","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1126\/science.1090922","volume":"303","author":"NA Bhowmick","year":"2004","unstructured":"Bhowmick, N. A. et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848\u2013851 (2004).","journal-title":"Science"},{"key":"3307_CR52","doi-asserted-by":"publisher","first-page":"e87680","DOI":"10.1172\/jci.insight.87680","volume":"1","author":"Y Sato","year":"2016","unstructured":"Sato, Y. et al. Heterogeneous fibroblasts underlie age-dependent tertiary lymphoid tissues in the kidney. JCI Insight 1, e87680 (2016).","journal-title":"JCI Insight"},{"key":"3307_CR53","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S1044-5323(02)00123-9","volume":"15","author":"MM Wong","year":"2003","unstructured":"Wong, M. M. & Fish, E. N. Chemokines: attractive mediators of the immune response. Semin. Immunol. 15, 5\u201314 (2003).","journal-title":"Semin. Immunol."},{"key":"3307_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14600","volume":"8","author":"JC Klein","year":"2017","unstructured":"Klein, J. C. et al. Combined toll-like receptor 3\/7\/9 deficiency on host cells results in T-cell-dependent control of tumour growth. Nat. Commun. 8, 14600 (2017).","journal-title":"Nat. Commun."},{"key":"3307_CR55","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1053\/j.gastro.2009.10.057","volume":"138","author":"B Mlecnik","year":"2010","unstructured":"Mlecnik, B. et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 138, 1429\u20131440 (2010).","journal-title":"Gastroenterology"},{"key":"3307_CR56","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960\u20131964 (2006).","journal-title":"Science"},{"key":"3307_CR57","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1182\/blood-2007-07-103119","volume":"111","author":"SF Wang","year":"2008","unstructured":"Wang, S. F. et al. Development of Notch-dependent T-cell leukemia by deregulated Rap1 signaling. Blood 111, 2878\u20132886 (2008).","journal-title":"Blood"},{"key":"3307_CR58","doi-asserted-by":"publisher","first-page":"9967","DOI":"10.1158\/0008-5472.CAN-06-1346","volume":"66","author":"K Kometani","year":"2006","unstructured":"Kometani, K. et al. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model. Cancer Res. 66, 9967\u20139976 (2006).","journal-title":"Cancer Res."},{"key":"3307_CR59","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.immuni.2014.10.011","volume":"41","author":"M Sekai","year":"2014","unstructured":"Sekai, M., Hamazaki, Y. & Minato, N. Medullary thymic epithelial stem cells maintain a functional thymus to ensure lifelong central T cell tolerance. Immunity 41, 753\u2013761 (2014).","journal-title":"Immunity"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03307-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03307-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03307-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:20:28Z","timestamp":1671542428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03307-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,2]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["3307"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-03307-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,2]]},"assertion":[{"value":"2 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was supported in part by research funding from Sumitomo Dainippon Pharma Co., Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"914"}}